Harmony Biosciences Holdings (HRMY) Other Non-Current Assets (2019 - 2026)
Harmony Biosciences Holdings (HRMY) reported Other Non-Current Assets of $26.4 million for Q1 2026, up 9690.0% on a YoY basis from $270000.0 in Q1 2025, and up 43.87% sequentially from $18.4 million in Q4 2025.
Harmony Biosciences Holdings (HRMY) Other Non-Current Assets (2019 - 2026) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 8 years of Other Non-Current Assets data on file, last reported at $26.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 9690.0% year-over-year to $26.4 million; the trailing twelve-month figure through Mar 2026 stood at $26.4 million (up 9690.0% YoY), and the FY2025 full-year result was $18.4 million, up 6704.81% from the prior year.
- Other Non-Current Assets rose to $26.4 million in Q1 2026, from $18.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $26.4 million in Q1 2026 to a low of $250000.0 in Q2 2023.
- A 5-year average of $3.9 million and a median of $750000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Across the five-year window, Other Non-Current Assets plunged 95.82% in 2025 and surged 9690.0% in 2026, its largest moves.
- Tracing HRMY's Other Non-Current Assets over 5 years: stood at $750000.0 in 2022, then slumped by 64.0% to $270000.0 in 2023, then changed by 0.0% to $270000.0 in 2024, then jumped by 6704.81% to $18.4 million in 2025, then surged by 43.87% to $26.4 million in 2026.
- Business Quant data shows HRMY's Other Non-Current Assets at $26.4 million in Q1 2026, $18.4 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.02 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 104.24 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.26 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.13 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 124.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 14.48 Mn |
| 10 | Harmony Biosciences Holdings | 2.07 Bn | 1.55 Bn | 170.88 Mn | 26.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 26.43 Mn |
| Dec 31, 2025 | 18.37 Mn |
| Sep 30, 2025 | 9.69 Mn |
| Jun 30, 2025 | 270,000.00 |
| Mar 31, 2025 | 270,000.00 |
| Dec 31, 2024 | 270,000.00 |
| Sep 30, 2024 | 270,000.00 |
| Jun 30, 2024 | 6.47 Mn |
| Mar 31, 2024 | 270,000.00 |
| Dec 31, 2023 | 270,000.00 |
| Sep 30, 2023 | 250,000.00 |
| Jun 30, 2023 | 250,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Sep 30, 2022 | 750,000.00 |
| Jun 30, 2022 | 750,000.00 |
| Mar 31, 2022 | 750,000.00 |
| Dec 31, 2021 | 750,000.00 |
| Sep 30, 2021 | 750,000.00 |
| Jun 30, 2021 | 750,000.00 |